Healthcare Innovation Communications

HealthTech PR Agency

Navigate healthcare's complex regulatory landscape while building clinical credibility for your digital health, telemedicine, medical device, or healthcare AI innovation. From FDA announcements to HIPAA-compliant patient stories, we secure healthcare trade coverage, clinical journal citations, and physician endorsements that drive provider adoption and patient trust.

Start Your Campaign View Case Studies

1,000+ Tech Companies Served

20+ Years Experience

100K+ Media Placements

33 Awards Won

Our Track Record

SlicedBrand HealthTech PR Expertise

1,000+ Tech Companies Served

Including 150+ healthtech clients across digital health platforms, telemedicine, medical devices, healthcare AI, health IT, remote patient monitoring, digital therapeutics, genomics, and health data analytics verticals since 2006. Our portfolio spans early-stage digital health startups, mid-market medical device manufacturers, and enterprise health IT platforms.

20+ Years Experience

Two decades navigating healthcare's regulatory complexity from FDA approval processes to HIPAA compliance, clinical validation requirements, and reimbursement policy changes. We've communicated through major healthcare industry shifts including the HITECH Act, Affordable Care Act provisions, telehealth expansion during COVID-19, and the current AI-in-healthcare transformation.

100K+ Media Placements

Secured coverage across STAT News, MedCity News, Fierce Healthcare, Healthcare IT News, MobiHealthNews, plus mainstream tech outlets including TechCrunch Health, Forbes Healthcare, and Wall Street Journal health technology coverage. Our placements span FDA clearance announcements, clinical study results, thought leadership, provider adoption stories, and patient outcome communications across traditional healthcare trade publications, clinical journals, technology media, and healthcare podcasts.

33 Awards Won

Recognition for healthtech PR excellence including Best Healthcare Technology Campaign, Outstanding Medical Device Launch, and Excellence in Patient Communications. Our award-winning campaigns demonstrate mastery across regulatory announcements, clinical validation storytelling, multi-stakeholder messaging, and crisis communications for healthcare controversies including data breaches, patient safety concerns, and clinical efficacy questions.

Industry Challenges

Why HealthTech Needs Specialized PR

Healthcare technology communications require navigating regulatory complexity, clinical validation standards, patient privacy laws, and multi-stakeholder audiences that fundamentally differ from consumer technology PR.

Healthcare Media Ecosystem

HealthTech Media Landscape

Effective healthtech PR requires coordinated outreach across three distinct media tiers, each serving different roles in clinical credibility building, stakeholder awareness, and market validation.

Tier 1: Healthcare Trade Publications

STAT News (healthcare & pharma)
MedCity News (digital health focus)
Fierce Healthcare (health systems)
Healthcare IT News (health IT)
MobiHealthNews (mobile/digital health)
Healthcare Dive (industry news)
Becker's Hospital Review (hospital ops)
Modern Healthcare (C-suite audience)
Health Data Management (analytics)
Medical Device & Diagnostic (devices)

Tier 2: Technology & Business Media

TechCrunch (health vertical)
Forbes Healthcare
Wall Street Journal (health tech)
Fast Company (health innovation)
VentureBeat (AI healthcare)
MIT Technology Review (research)
Wired (digital health)
The Information (health tech)
Business Insider (healthcare)
Fortune (healthcare business)

Tier 3: Specialty & Emerging Media

The Medical Futurist (innovation)
Rock Health (VC perspective)
Digital Health News (Europe)
Medical Design & Outsourcing
Health Tech Podcast (interviews)
The Digital Health Podcast
Connected Health Conference
HIMSS (health IT community)
Clinical journals (specialty-specific)
Patient advocacy publications

Featured Case Study

AI Radiology Platform FDA Clearance

A Series B artificial intelligence diagnostics company received FDA 510(k) clearance for their deep learning algorithm detecting critical findings in chest X-rays. Despite strong clinical validation from multi-site trials, they faced significant market challenges: radiologists skeptical of AI accuracy, health systems hesitant about clinical workflow integration, and payers uncertain about reimbursement pathways. The competitive landscape included 50+ radiology AI companies making similar claims about accuracy improvements, creating noise where differentiation required more than regulatory clearance alone. Their clinical team had invested three years in rigorous validation studies, but translating technical performance metrics into compelling market narratives that resonated with physician buyers, hospital IT decision-makers, and payer medical directors required specialized healthcare communications expertise beyond generic technology PR approaches.

The Challenge

The AI diagnostics company faced multiple healthcare-specific communications barriers:

Differentiate from 50+ competing radiology AI vendors making similar accuracy claims in crowded market
Build radiologist trust overcoming physician skepticism about AI replacing clinical judgment and diagnostic autonomy
Demonstrate clinical workflow integration showing how AI augments rather than disrupts existing radiology reading processes
Secure healthcare trade coverage in STAT News, MedCity News, and Healthcare IT News beyond generic FDA clearance announcements
Generate physician testimonials from early adopter radiologists willing to publicly endorse AI technology despite specialty controversies
Position FDA clearance as clinical validation milestone rather than mere regulatory checkbox in market saturated with cleared algorithms
Address reimbursement uncertainty communicating path to payer coverage despite lack of dedicated CPT codes for AI-assisted radiology

Strategic Process

We developed a clinical credibility strategy emphasizing rigorous validation methodology and physician partnership over generic AI accuracy claims:

Positioning around multi-site validation study methodology differentiating from single-center studies common among competitors
Identifying physician-partnership narrative emphasizing AI as clinical decision support tool augmenting radiologist expertise rather than replacement technology
Creating compelling clinical outcome data visualization translating AUC scores and sensitivity metrics into patient impact stories
Recruiting chief medical officer of early adopter health system as credible third-party spokesperson for media interviews
Targeting healthcare trade journalists with clinical backgrounds who could evaluate validation rigor rather than tech reporters lacking medical expertise
Coordinating FDA clearance timing with peer-reviewed publication in Radiology journal providing dual validation moments

Execution Strategy

We executed a multi-channel campaign building clinical credibility across healthcare media, physician networks, and industry conferences:

Pre-Announcement Phase: Conducted embargoed briefings with STAT News and Healthcare IT News providing detailed validation data, physician interviews, and exclusive early access generating in-depth feature coverage rather than brief news items
FDA Clearance Announcement: Coordinated press release with healthcare trade coverage, radiology journal publication, and early adopter health system case study generating 35 healthcare media placements within 72 hours
Clinical Conference Activation: Secured podium presentation at RSNA (Radiological Society of North America) annual meeting enabling physician-to-physician credibility building and generated 15 additional media interviews at conference
Physician Thought Leadership: Developed clinical white paper co-authored with radiologist advisors positioning validation methodology and published in peer-reviewed health IT journal
Provider Adoption Stories: Created ongoing case study series featuring early adopter health systems, radiologist testimonials, and patient outcome data sustaining media interest beyond initial clearance announcement

Results Delivered

The campaign exceeded clinical credibility, media coverage, and commercial traction targets:

Healthcare Media Coverage: 45 articles across tier-1 healthcare trade including STAT News feature, MedCity News interview, Healthcare IT News analysis, plus coverage in 8 radiology specialty publications generating 2.8M healthcare professional impressions
Clinical Journal Citations: 12 citations in peer-reviewed clinical journals referencing FDA clearance and validation methodology establishing academic credibility
Physician Endorsements: Public testimonials from 8 radiologists at academic medical centers including quotes in media coverage, conference presentations, and case study participation
Provider Inquiries: 200+ inbound health system inquiries within 60 days of FDA clearance announcement, 35 pilot implementations initiated, 12 enterprise contracts signed within 6 months
Industry Recognition: Nominated for Digital Health Most Promising AI Company, selected for HIMSS Innovation Showcase, invited to present at Connected Health Conference
Investor Validation: Media coverage and clinical credibility contributed to $28M Series C funding round led by prominent healthcare-focused VC, with press coverage citing strong clinical validation and physician adoption as key investment thesis factors

"SlicedBrand understood that FDA clearance alone wasn't differentiation in radiology AI—every competitor had clearances. They positioned our multi-site validation rigor and physician partnership approach as the real story, which resonated with radiologists skeptical of AI vendors making exaggerated accuracy claims without robust clinical evidence."

Chief Medical Officer

AI Radiology Platform

"This represents the kind of rigorous clinical validation we need to see from AI diagnostic companies. The multi-site study design, transparent performance metrics, and physician co-development approach differentiate this platform from the dozens of radiology AI vendors making similar claims based on limited single-center studies."

Senior Health Technology Reporter

STAT News

"The PR campaign directly contributed to our commercial traction. Health systems told us they chose our platform over competitors specifically because of our clinical credibility—the media coverage, radiologist testimonials, and peer-reviewed publications gave procurement committees confidence our technology was clinically validated, not just venture-funded hype."

VP of Marketing

AI Radiology Platform

Industry Evolution

HealthTech Trends 2025

The healthcare communications landscape continues evolving rapidly. Successful PR strategies must adapt to regulatory changes, clinical validation requirements, and shifting stakeholder priorities.

🧠

Healthcare AI Regulation Intensifies

FDA's evolving regulatory framework for AI/ML-based medical devices creates both opportunities and compliance challenges. The agency's predetermined change control plans, algorithm performance monitoring requirements, and post-market surveillance obligations establish new standards for AI transparency and continuous validation. Healthcare PR must navigate communications about algorithm updates, performance drift monitoring, and ongoing validation while maintaining physician trust through transparent disclosure practices that balance innovation velocity with appropriate regulatory oversight and clinical safety prioritization.

💻

Interoperability as Competitive Advantage

FHIR API adoption and health information exchange connectivity transform from nice-to-have features to essential requirements as ONC's information blocking regulations take effect. Payers and health systems increasingly demand seamless data exchange, EHR integration, and patient data access capabilities. Healthcare PR should proactively highlight interoperability achievements, FHIR certification, patient data access features, and health information exchange participation demonstrating commitment to connected healthcare ecosystems rather than proprietary data silos hindering care coordination across fragmented delivery systems.

💰

Value-Based Care Messaging Evolution

Shift from fee-for-service to value-based payment models requires healthcare technology vendors to demonstrate ROI through quality metrics, readmission reduction, total cost of care impact, and population health outcomes rather than productivity gains or efficiency improvements alone. Healthcare PR must position solutions in economic terms resonating with CFOs, payer medical directors, and ACO leaders making coverage and adoption decisions based on cost-effectiveness, quality measure performance, and risk-adjusted outcome improvements rather than clinical efficacy claims alone that fail to address healthcare's increasing cost containment imperatives.

👤

Health Equity & Disparity Communications

Healthcare stakeholders increasingly prioritize health equity considerations evaluating whether technologies reduce or exacerbate existing healthcare disparities across race, socioeconomic status, geography, and language barriers. Algorithm bias concerns, digital divide access issues, and culturally appropriate design require proactive communication addressing diverse population needs. Healthcare PR should highlight diverse patient representation in clinical validation, accessibility features, language support, bias testing methodologies, and community partnerships demonstrating authentic commitment to health equity rather than diversity-washing rhetoric lacking substantive features addressing systemic barriers to care access and quality.

🏥

Mental Health Tech Destigmatization

Mental health technology gains mainstream acceptance as COVID-19 normalized teletherapy and reduced stigma around mental healthcare. Digital therapeutics for depression, anxiety apps, virtual psychiatry platforms, and mental wellness solutions transition from niche offerings to essential healthcare services. Communications require sensitive balance celebrating mental health access improvements while maintaining clinical seriousness, avoiding wellness-washing of medical conditions, ensuring evidence-based positioning, and addressing unique privacy concerns around especially sensitive mental health data that carries employment, insurance, and social relationship implications beyond typical health information protection requirements.

💊

Decentralized Clinical Trial Communications

Decentralized clinical trials using telemedicine, wearables, and electronic consenting enable broader patient participation beyond traditional academic medical centers. Communications must address participant recruitment, remote monitoring technologies, data quality assurance, and regulatory acceptance while highlighting democratization of research participation, reduced patient burden, improved diversity, and faster enrollment. Healthcare PR should position DCT capabilities as competitive advantages for sponsors while addressing investigator concerns about data integrity, regulatory compliance, and scientific rigor ensuring remote trial conduct maintains gold-standard clinical research quality expectations.

Industry Standards

HealthTech PR Best Practices

Two decades of healthcare PR experience distilled into foundational principles separating successful campaigns from regulatory scrutiny and stakeholder skepticism.

Clinical Evidence Before Marketing Claims

Healthcare communications must begin with rigorous clinical validation through peer-reviewed research, randomized trials, or real-world evidence before public claims about efficacy, safety, or clinical outcomes. Lead with validated evidence, cite peer-reviewed sources, acknowledge study limitations, and distinguish between preliminary findings and proven results. Healthcare stakeholders aggressively scrutinize claims lacking substantiation—credibility damaged by premature announcements or exaggerated benefits rarely recovers. Invest in clinical validation before PR rather than attempting to build credibility without evidence foundation that healthcare's scientifically trained audiences demand.

Regulatory Compliance as Foundation

Every healthcare communication must meet FDA marketing regulations, HIPAA privacy requirements, FTC substantiation standards, and healthcare advertising restrictions before publication. Establish legal review processes, collaborate with regulatory affairs teams, maintain compliant claims libraries, and document evidence supporting all statements about safety, efficacy, or clinical outcomes. Regulatory violations create legal liability, enforcement actions, and reputational damage far exceeding any commercial benefit gained from aggressive marketing claims. Conservative, compliant messaging builds long-term credibility while aggressive claims trigger scrutiny destroying stakeholder trust and creating regulatory headaches requiring years to resolve.

Physician Credibility as Third-Party Validation

Physician testimonials and clinical advisor quotes provide essential third-party validation that company claims alone cannot achieve. Recruit respected clinicians as advisors, facilitate media interviews with physician spokespersons, showcase early adopter health system implementations, and leverage clinical society relationships building authentic clinical credibility. Healthcare buyers trust physician peers over vendor marketing materials—communications lacking clinical voices lack persuasive power with physician, health system, and payer audiences making adoption decisions based on peer recommendations and clinical community consensus rather than vendor claims regardless of evidence quality.

Patient Safety Above Commercial Objectives

Healthcare communications carry ethical responsibilities beyond typical technology marketing. Patient safety must always be paramount—never overstate capabilities, create unrealistic expectations, imply guarantees about health outcomes, or encourage patients to delay proper medical treatment. Include appropriate disclaimers about consulting healthcare providers, acknowledge treatment limitations honestly, and maintain transparency about what technology can and cannot achieve. Healthcare community has long memories for companies prioritizing marketing over patient welfare—reputation damage from perceived ethical violations persists for years and destroys stakeholder trust impossible to rebuild through subsequent good behavior.

Multi-Stakeholder Messaging Segmentation

Healthcare's complex buying ecosystem requires segmented messaging strategies tailored to physicians, patients, payers, health systems, and regulators rather than generic messaging attempting to serve all audiences simultaneously. Develop distinct value propositions: clinical efficacy for physicians, accessibility for patients, cost-effectiveness for payers, implementation ease for health systems, compliance for regulators. Maintain consistent brand positioning while adapting evidence types, communication channels, and language complexity appropriate for each stakeholder's decision-making criteria and information needs. One-size-fits-all messaging fails to resonate with any healthcare audience segment given fundamentally different priorities across stakeholders.

Healthcare Media Relationship Investment

Healthcare journalists require different relationship approaches than technology reporters. Healthcare media expects clinical accuracy, regulatory compliance, and evidence substantiation rather than hype, aggressive growth claims, or unproven innovation narratives. Build long-term relationships through reliable information, expert source access, clinical data transparency, and acknowledgment of limitations rather than one-off transactional pitches. Healthcare reporters consult clinical advisors verifying claims, scrutinize study methodology, and challenge unsupported statements—attempting to spin or obscure limitations destroys credibility permanently. Treat healthcare journalists as clinical peers requiring respect, accuracy, and transparency rather than publicity channels you control.

Transparent Data Privacy Communication

Healthcare data breaches generate massive reputational consequences requiring proactive privacy and security communication before controversies emerge. Transparently communicate data practices, third-party security audits, encryption protocols, access controls, patient consent mechanisms, and breach notification procedures demonstrating genuine commitment to privacy protection beyond legal compliance minimums. Consumer health apps face particular scrutiny over data sharing with advertisers, pharmaceutical companies, or research partners. Genetic testing and mental health platforms handle especially sensitive information. Vague privacy reassurances lack credibility—provide technical specifics demonstrating substantive data governance rather than privacy policy legalese providing false reassurance.

Reimbursement Pathway Clarity

Healthcare adoption requires clear reimbursement pathways regardless of clinical efficacy. Proactively address payment uncertainty through communication about payer coverage policies, CPT coding status, Medicare/Medicaid reimbursement, and commercial insurer contracts. Telemedicine platforms communicate payment parity laws, medical devices highlight coverage determinations, digital therapeutics explain prescription pathways. Healthcare buyers postpone adoption decisions when reimbursement uncertainty creates financial risk regardless of clinical enthusiasm. Incorporate reimbursement milestone communications (coverage policy wins, coding approvals, payer partnerships) into ongoing PR strategy recognizing payment clarity often matters more than clinical validation for actual healthcare purchasing decisions in fee-for-service dominated delivery systems.

Ready to Launch Your HealthTech Innovation?

Let's discuss your healthcare communications needs and create a strategic campaign that navigates regulatory complexity, builds clinical credibility, and drives stakeholder adoption from FDA clearance through sustained market success.

Start Your Campaign

Common Questions

HealthTech PR FAQ

How do you ensure healthcare PR complies with FDA regulations? +

We establish rigorous compliance processes including legal review of all materials, collaboration with your regulatory affairs team, maintenance of approved claims language libraries, and documentation of clinical evidence supporting every efficacy, safety, or outcome statement. All communications reference FDA-cleared indications, approved labeling language, and peer-reviewed evidence while avoiding off-label implications or unsubstantiated comparative claims. We distinguish between Class I/II/III devices with appropriate regulatory context, properly communicate 510(k) predicate equivalence versus De Novo novelty, and ensure all materials could withstand FDA scrutiny during inspections or enforcement reviews. Our team includes former medical device communications professionals with deep regulatory affairs experience beyond generic tech PR knowledge.

What makes healthtech PR different from general tech PR? +

HealthTech PR operates within strict regulatory frameworks (FDA, HIPAA, FTC) requiring substantiated claims, clinical evidence, and patient privacy protection absent in consumer technology. Healthcare stakeholders—physicians, health systems, payers—demand evidence-based messaging, peer-reviewed validation, and conservative benefit statements rather than growth-focused hype common in technology PR. Healthcare journalists have clinical training evaluating study methodology, statistical significance, and limitations that technology reporters lack. Patient safety considerations create ethical obligations beyond typical product marketing. Healthcare's multi-stakeholder complexity requires segmented messaging for clinicians, patients, payers, and regulators with fundamentally different priorities. Generic tech PR approaches promoting "disruptive" innovation, unsupported benefits, or aggressive growth narratives fail in healthcare's evidence-demanding, patient-safety-focused culture where credibility builds slowly through consistent clinical validation rather than launch-day hype.

Can you help position our healthcare AI while addressing algorithm bias concerns? +

Yes, we develop comprehensive AI communications addressing algorithm transparency, bias testing, and equity considerations that healthcare stakeholders increasingly demand. Our approach includes: (1) Transparent communication about training data diversity, validation dataset demographics, and subgroup performance analysis demonstrating equitable algorithm performance across patient populations. (2) Proactive disclosure of bias testing methodologies, fairness metrics, and ongoing performance monitoring addressing concerns before critics raise questions. (3) Physician-in-the-loop positioning emphasizing clinical oversight, explainable AI features, and decision support framing rather than autonomous AI replacement narratives physicians distrust. (4) Health equity messaging highlighting how AI extends specialist expertise to underserved communities, reduces diagnostic disparities, or improves access rather than exacerbating digital divide. (5) Regulatory compliance communication around FDA's evolving AI/ML guidance including predetermined change control plans and algorithm performance monitoring. We help position AI as augmenting clinical judgment through transparent, equitable, physician-supervised approaches rather than "black box" algorithms triggering physician resistance and equity concerns.

How do you handle HIPAA compliance in patient testimonials and case studies? +

We maintain strict HIPAA compliance through multiple safeguards: (1) Written Authorization: Obtain HIPAA-compliant patient authorization forms specifically permitting use of health information for marketing purposes, distinct from general treatment consent. (2) De-identification: Remove all 18 HIPAA identifiers (names, dates, locations, photos, etc.) when creating anonymized case studies that don't require individual authorization. (3) Limited Disclosure: Share only minimum necessary health information relevant to testimonial purpose, avoiding unnecessary clinical details. (4) Legal Review: All patient-facing materials reviewed by healthcare privacy counsel ensuring compliance with both HIPAA and state privacy laws. (5) Aggregated Data: Prefer population-level outcome statistics over individual patient stories when possible, eliminating privacy concerns. (6) Provider Testimonials: Focus on physician and health system case studies describing implementation experiences without patient identifiers. We coordinate closely with your privacy officer and legal team ensuring all patient communications meet HIPAA requirements while maintaining compelling storytelling impact.

What clinical evidence do we need before launching healthcare PR campaigns? +

Minimum evidence requirements vary by product type and claims: Medical Devices: FDA clearance/approval documentation, clinical trial data supporting cleared indications, and ideally peer-reviewed publication in relevant clinical journal (e.g., JAMA, Radiology, Circulation). Digital Health Platforms: Real-world evidence from pilot implementations, patient outcome data (engagement rates, adherence improvements, health metrics), and provider testimonials from early adopters. Healthcare AI: Validation study results including sensitivity/specificity metrics, AUC scores, performance across demographic subgroups, and comparison to physician baseline or clinical standard of care. Health IT Systems: Implementation case studies from recognized health systems, workflow integration documentation, and interoperability certifications. All Categories: Competitive differentiation data, cost-effectiveness analysis, and reimbursement pathway clarity. We conduct clinical evidence audits during planning identifying gaps requiring additional validation before public campaigns. Strong PR campaigns begin with strong clinical foundations—attempting to build credibility without evidence wastes budget and damages reputation when healthcare audiences demand substantiation that generic innovation narratives cannot provide.

How long does it take to see healthcare media coverage results? +

Healthcare media timelines differ significantly from consumer technology: Regulatory Announcements (FDA clearances, clinical trial results): 2-4 weeks from announcement to initial coverage as healthcare journalists evaluate clinical significance, interview external experts, and fact-check claims more rigorously than tech reporters. Thought Leadership & Features: 8-12 weeks as healthcare trade editors develop editorial calendars months in advance and clinical validation takes time to establish credibility. Conference Coverage: Immediate to 2 weeks around major healthcare conferences (HIMSS, RSNA, AHA) when media concentration enables rapid interview opportunities. Sustained Clinical Credibility: 6-12 months to establish genuine clinical credibility through consistent evidence communication, physician endorsements, and provider adoption momentum demonstrating staying power beyond initial launch hype. Healthcare stakeholder trust builds gradually—realistic expectations recognize that clinical credibility requires sustained effort rather than overnight breakthrough moments common in consumer technology. Budget campaigns accordingly with 3-6 month minimum commitments rather than expecting immediate coverage generating instant commercial traction in healthcare's characteristically conservative, evidence-demanding adoption cycles.

Do you help with health system implementation announcements? +

Yes, health system implementation announcements provide powerful validation signaling clinical credibility, operational feasibility, and real-world effectiveness to prospective buyers. We coordinate: (1) Joint Announcements: Collaborate with health system marketing/communications teams navigating their approval processes, timeline constraints, and messaging preferences. (2) Clinical Champion Identification: Recruit physician or IT leader spokespersons from implementing institutions providing credible third-party validators for media interviews. (3) Implementation Details: Communicate deployment scale (number of providers, patient population, clinical specialties), workflow integration, staff training, and go-live timeline demonstrating operational complexity successfully navigated. (4) Outcome Data: Share preliminary results including adoption rates, utilization metrics, efficiency gains, or clinical outcome improvements even when formal studies remain incomplete. (5) Multi-Tier Media Strategy: Target both healthcare trade (announcing institutional validation) and local business media (celebrating regional health system innovation) maximizing coverage angles. (6) Case Study Development: Transform announcements into detailed written case studies, video testimonials, and conference presentations extending PR value beyond initial news cycle. Health system logos and implementation stories provide essential credibility signals accelerating subsequent sales cycles with risk-averse healthcare buyers.

Can you help position our solution for value-based care contracts? +

Yes, as healthcare shifts toward value-based payment models, we help position solutions in economic terms resonating with payers, ACOs, and health systems managing financial risk under capitated contracts. Our approach includes: (1) ROI Communications: Translate clinical benefits into economic outcomes including cost per episode reduction, total cost of care impact, readmission prevention savings, or emergency department utilization decreases. (2) Quality Metric Positioning: Highlight performance on CMS quality measures (HEDIS, MIPS, hospital star ratings) that directly impact value-based payment bonuses or penalties. (3) Population Health Framing: Position solutions enabling risk stratification, care gap identification, chronic disease management, and preventive care coordination essential for managing attributed patient populations. (4) Payer Partnership Announcements: Communicate Medicare Advantage contracts, Medicaid managed care implementations, or commercial payer coverage policies validating economic value propositions. (5) Actuarial Analysis: Develop cost-effectiveness models, budget impact analyses, and medical loss ratio improvements demonstrating financial sustainability under capitated payment. We help translate clinical innovation into financial outcomes language that CFOs, payer medical directors, and accountable care leaders use when making adoption decisions increasingly driven by economic necessity rather than clinical enthusiasm alone in value-based care environment.

How do you measure healthcare PR campaign success? +

Healthcare-specific measurement frameworks track both awareness metrics and commercial outcomes: Media Coverage Metrics: Healthcare trade placements (STAT News, MedCity News, Fierce Healthcare), clinical journal citations, mainstream media coverage (WSJ, Forbes healthcare), tier-1 outlet percentage, message pull-through rates, and healthcare professional impressions. Credibility Indicators: Physician testimonials secured, health system case studies published, clinical advisor recruitment, peer-reviewed publications amplified, and conference speaking invitations. Stakeholder Engagement: Healthcare professional website traffic, white paper downloads, clinical webinar attendance, and physician inquiry volume. Commercial Impact: Provider demonstration requests, health system pilot implementations, enterprise contract progression, and sales cycle length reduction. Clinical Validation: Peer-reviewed publication citations, clinical society endorsements, and FDA expansion clearances built on market presence. Business Outcomes: Revenue attribution from PR-sourced leads, customer acquisition cost comparison to paid channels, and investor interest (funding, valuation, strategic partnerships). Effective healthcare PR demonstrates 8-20x ROI compared to paid advertising when measuring total impact including credibility building, thought leadership, and stakeholder trust that paid channels cannot replicate in healthcare's relationship-driven, evidence-focused buying environment where third-party validation matters exponentially more than vendor claims.

What happens if we receive an FDA warning letter during our PR campaign? +

FDA warning letters require immediate response with transparent, accountable communication: (1) Immediate Pause: Halt all promotional activities pending legal and regulatory review of warning letter scope, violations cited, and corrective actions required. (2) Legal Coordination: Collaborate with regulatory counsel developing response strategy, corrective action plan, and revised claims language addressing FDA concerns. (3) Stakeholder Communication: Prepare transparent statement acknowledging warning letter, explaining corrective actions, reaffirming patient safety commitment, and providing realistic timeline for resolution. (4) Media Response: Respond to healthcare media inquiries with prepared statements emphasizing cooperation with FDA, corrective measures implemented, and commitment to regulatory compliance avoiding defensive tone or minimization. (5) Customer Reassurance: Proactively contact existing customers explaining situation, clarifying whether products remain FDA-cleared for current use, and communicating remediation timeline. (6) Corrective Action Amplification: Once FDA accepts corrective measures, proactively communicate resolution demonstrating responsive regulatory partnership. (7) Long-term Reputation Rebuilding: Sustained evidence communication, physician testimonials, and clinical validation rebuilding stakeholder trust damaged by regulatory scrutiny. Healthcare community understands regulatory complexity—transparent, accountable responses maintain credibility while defensive deflection causes permanent reputational damage. We've successfully navigated multiple clients through FDA warning letters minimizing commercial impact through strategic, transparent crisis communications.